Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
2026 Melanoma Guidelines Update: NCCN and AAD Changes, Overdiagnosis, and New Treatment Approaches
Description
The talk reviews 2026 melanoma guideline updates from NCCN and AAD, explaining that NCCN is a large, evidence-based, frequently updated, globally used guideline system with increasing dermatology representation, while AAD guidelines remain more static but important for earlier-stage disease. Major themes include rising melanoma incidence and concern for overdiagnosis, especially melanoma in situ, with discussion of a possible future relabeling of in situ lesions and the new NCCN option of observation for melanoma in situ in patients with poor functional status or limited life expectancy. Surgical management changes include continued excision as standard, possible topical imiquimod for lentigo maligna in nonsurgical candidates, and efforts to reduce surgical margins through ongoing trials. The speaker also discusses the growing role of gene expression profiling and multivariable risk tools to help guide sentinel node biopsy decisions in selected T1B/T2A patients. For advanced disease, baseline PET-CT is now considered appropriate in higher-risk stage 2B/2C patients, and if imaging reveals nodal disease, upfront neoadjuvant immunotherapy is recommended for stage 3 melanoma before surgery, with pathologic response guiding further treatment. Overall, the lecture emphasizes more individualized, less invasive, and more multidisciplinary melanoma care.
View moreConclusions
- The updated melanoma guidelines increasingly prioritize dynamic, evidence-based changes driven by rapidly evolving immunotherapy and surgical trial data.
- Melanoma in situ is being recognized as a major area of possible overdiagnosis, prompting consideration of less aggressive management in carefully selected patients.
- Surgical excision remains standard for melanoma in situ, but observation can be appropriate for patients with poor functional status or limited life expectancy, and topical imiquimod is a reasonable option for lentigo maligna in non-surgical candidates.
- Gene expression profiling and multivariable risk models may help refine sentinel lymph node biopsy decision-making in select thin melanoma patients, but their role remains modest and adjunctive.
- There is a broad trend toward de-escalating surgical margins for invasive melanoma, especially for thinner tumors, as ongoing trials test whether narrower margins are oncologically safe.
- Baseline imaging is increasingly important for clinically stage IIB/IIC melanoma when adjuvant therapy is being considered, because occult nodal disease may be detected before surgery.
- For clinically stage III melanoma, upfront neoadjuvant immunotherapy is favored over immediate surgery, with pathology response serving as an important predictor of survival and subsequent treatment need.
- The presentation suggests that stage II melanoma management is likely to shift further toward earlier imaging and possibly neoadjuvant approaches as evidence matures.
- J Am Acad Dermatol. 2019;80:208-250.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 1.2026, February 17, 2026.
- NEJM 2023; NEJM 2024 (neoadjuvant immunotherapy / stage III melanoma studies)